title: Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota.
abstract: Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinctBacteroidesspecies of the gut microbiota, signifying novel approaches to improve such immunotherapies.
authors.affiliation: Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM Unit U1015, Villejuif, France; Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France.
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Pitt
authors.affiliation: Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM Unit U1015, Villejuif, France; Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Vétizou
authors.affiliation: Institut Pasteur, Unit of Biology and Genetics of the Bacterial Cell Wall, Paris, France; INSERM, Equipe Avenir, Paris, France.
authors.forename: Ivo
authors.initials: I
authors.lastname: Gomperts Boneca
authors.affiliation: Institut National de la Recherche Agronomique (INRA), Micalis-UMR1319 , Jouy-en-Josas, France.
authors.forename: Patricia
authors.initials: P
authors.lastname: Lepage
authors.affiliation: University of Lille, CNRS, INSERM, Center Hospitalier Régional Universitaire de Lille, Institut Pasteur de Lille, U1019, UMR 8204, Center d'Infection et d'Immunité de Lille (CIIL) , Lille, France.
authors.forename: Mathias
authors.initials: M
authors.lastname: Chamaillard
authors.affiliation: Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM Unit U1015, Villejuif, France; Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France; INSERM Unit U932, Institut Curie, Paris Cedex 05, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
keywords: Anti-CTLA-4; Bacteroides; T cell; cancer; ipilimumab; microbiome; microbiota